-
Mashup Score: 16Evolution of Gamma Knife Technology | Cleveland Clinic - 3 month(s) ago
Listen as Dr. Chao takes us through gamma knife’s history, the current advantages and considerations, as well as potential future advances in the field.
Source: my.clevelandclinic.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Metabolomic Differences: Young Onset (yoCRC) vs. Average Onset (aoCRC) Colorectal Cancer - 7 month(s) ago
Listen as Dr. Kamath talks about the challenges associated with early detection, the evolving landscape of screening guidelines, potential contributing factors to the rise of yoCRC, and the role of metabolomics in unraveling the complexities of colorectal cancer.
Source: my.clevelandclinic.orgCategories: Latest Headlines, Oncologists1Tweet-
Tune in to this week's episode of the @CleClinicMD, Cancer Advances #podcast where I discuss our #ASCO23 study exploring metabolomic differences between young-onset CRC and average-onset colorectal cancer #CleClinicCancer https://t.co/giNq8nXliT @aakonc @ThejusJay
-
-
Mashup Score: 4Follow @JCO_ASCO on Twitter - 7 month(s) ago
Explore Art of Oncology’s rich collection of poignant essays and heartfelt poems sharing insights, emotions, and reflections on the human side of cancer medicine.
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Honored to be included in this collection of essays by writers whom I admire and from whom I have learned so much. #CleClinicCancer @CleClinicMD Art of Oncology Special Edition | Journal of Clinical Oncology https://t.co/iDQWtkxEJh
-
-
Mashup Score: 0Emerging Molecular Biomarkers for GU Cancer - 7 month(s) ago
Omar Mian, MD, PhD, radiation oncologist, and physician scientist, joins the Cancer Advances Podcast to talk about emerging molecular biomarkers for genitourinary cancers.
Source: my.clevelandclinic.orgCategories: Latest Headlines, UrologyTweet-
.@DrOmarMian joins @ShepardDale on the latest Cancer Advances podcast to talk about how biomarkers are revolutionizing the landscape of cancer care and innovations in PET scans and tracers for #prostatecancer. #CleClinicCancer https://t.co/sEHnaEGoWL
-
-
Mashup Score: 2Home | VeloSano - 8 month(s) ago
Latin for “swift cure,” VeloSano is Cleveland Clinic’s premier fundraising initiative in which 100% of every dollar raised supports lifesaving cancer research at Cleveland Clinic and Cleveland Clinic Children’s. Since its inception in 2014, over $37 million has been raised and has advanced over 200 cancer research projects.
Source: velosano.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
A great day for VeloSano 10!! @bikeVeloSano. 🚴♀️🚴 🚴♂️ Always amazed at the awesome turnout from so many volunteers 🙏 (like @ShinjiniGanguly and @huitingruan #MianLab) Thank you!! Not to late to support riders by going to https://t.co/yTtGV61DXu #CleClinicCancer https://t.co/o06o6DeBeQ https://t.co/yCuXvuYqa3
-
-
Mashup Score: 7
Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Acute GV…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
In July issue of @ASTCT_Journal: A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease; evaluation of FACT-BMT, PROMIS-10 and PRO-CTCAE in #GVHD by @sagarpatel @hamiltkyb et al #CleClinicCancer #BMTsm https://t.co/NcIIR3pgZs
-
-
Mashup Score: 7Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-vs-host disease prevention - 10 month(s) ago
Key Points. Compared to standard dose MTX, a reduced-dose MTX regimen incorporating MMF was associated with no significant differences in GVHD.Reduced dose MTX
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Congratulations @hamiltkyb et al @CleClinicMD #CleClinicCancer for 👇 randomized #GVHD prevention trial #BMTsm @BloodAdvances Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-vs-host disease prevention https://t.co/PkSmnXCjgR
-
-
Mashup Score: 0Clinical trial club | NCT03194542 trial: Luspatercept for the treatment of patients with anemic myelofibrosis - 11 month(s) ago
MPN Hub Symposium: NCT03194542 trial: Luspatercept for the treatment of patients with anemic myelofibrosis
Source: mpnhub-cme.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Thrilled to be joining @jjkiladjian for a journal club on June 28 to luspatercept and myelofibrosis! #mpnsm @MPN_Hub #CleClinicCancer https://t.co/1D0Uf3vcEL https://t.co/e5vRaNC8an
-
-
Mashup Score: 0Why Cancer Drugs Are Being Rationed - 11 month(s) ago
Politicians like to grouse about high drug prices. Well, now we’re s
Categories: Hem/Oncs, Latest HeadlinesTweet-
Why Cancer Drugs Are Being Rationed - The Wall Street Journal #CleClinicCancer I have no alternatives to cisplatin! https://t.co/6gV1k44S2p
-
-
Mashup Score: 0
OncLive® State of the Science Summit: Disease State, Month Day, Year. Oncology live event features research and clinical advances in oncology.
Source: event.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Participate: @OncLiveSOSS Hematology in-person education and networking event with @AaronGerds of @CleClinicMD. Expert faculty @paolocaimiMD Allison Winter, MD, @JohnMolinaMD Sandra Mazzoni, DO, @MukherzSudipto #SOSS #CleClinicCancer Register Today: https://t.co/aIzfXJY8C3 https://t.co/FwuYEOPhej
-
On the @CleClinicMD, Cancer Advances podcast this week, @SamuelChaoMD, Associate Director of the Gamma Knife Center, joins @ShepardDale to discuss the strides, evolution, and exciting future developments of gamma knife technology. #CleClinicCancer https://t.co/9Dp1SKUxdw